HIV-1 drug resistance and resistance testing
DS Clutter, MR Jordan, S Bertagnolio… - Infection, Genetics and …, 2016 - Elsevier
The global scale-up of antiretroviral (ARV) therapy (ART) has led to dramatic reductions in
HIV-1 mortality and incidence. However, HIV drug resistance (HIVDR) poses a potential …
HIV-1 mortality and incidence. However, HIV drug resistance (HIVDR) poses a potential …
HIV-1 antiretroviral drug therapy
EJ Arts, DJ Hazuda - Cold Spring Harbor …, 2012 - perspectivesinmedicine.cshlp.org
The most significant advance in the medical management of HIV-1 infection has been the
treatment of patients with antiviral drugs, which can suppress HIV-1 replication to …
treatment of patients with antiviral drugs, which can suppress HIV-1 replication to …
[HTML][HTML] 2019 update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez… - Topics in antiviral …, 2019 - ncbi.nlm.nih.gov
The 2019 edition of the IAS-USA drug resistance mutations list updates the Figure last
published in January 2017. The mutations listed are those that have been identified by …
published in January 2017. The mutations listed are those that have been identified by …
HIV-1 antiretroviral resistance: scientific principles and clinical applications
MW Tang, RW Shafer - Drugs, 2012 - Springer
The efficacy of an antiretroviral (ARV) treatment regimen depends on the activity of the
regimen's individual ARV drugs and the number of HIV-1 mutations required for the …
regimen's individual ARV drugs and the number of HIV-1 mutations required for the …
Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989 …
MP de Béthune - Antiviral research, 2010 - Elsevier
It is almost 20 years since NNRTIs were identified as a new class of antiretroviral drugs for
the treatment of HIV-1 infection. Although they belong to different and diverse chemical …
the treatment of HIV-1 infection. Although they belong to different and diverse chemical …
[HTML][HTML] 2011 update of the drug resistance mutations in HIV-1
VA Johnson, V Calvez, HF Günthard… - Topics in antiviral …, 2011 - ncbi.nlm.nih.gov
The development of more recently approved drugs that cannot be tested as monotherapy
precludes assessment of the impact of resistance on antiretroviral activity that is not …
precludes assessment of the impact of resistance on antiretroviral activity that is not …
[HTML][HTML] 2014 Update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez, HF Günthard… - Topics in antiviral …, 2016 - pmc.ncbi.nlm.nih.gov
Methods The IAS–USA Drug Resistance Mutations Group is an independent, volunteer
panel of experts charged with delivering accurate, unbiased, and evidence-based …
panel of experts charged with delivering accurate, unbiased, and evidence-based …
[HTML][HTML] HIV-1 drug resistance mutations: an updated framework for the second decade of HAART
RW Shafer, JM Schapiro - AIDS reviews, 2008 - ncbi.nlm.nih.gov
More than 200 mutations are associated with antiretroviral resistance to drugs belonging to
six licensed antiretroviral classes. More than 50 reverse transcriptase mutations are …
six licensed antiretroviral classes. More than 50 reverse transcriptase mutations are …
HIV and drug-resistant subtypes
BM Nastri, P Pagliano, C Zannella, V Folliero… - Microorganisms, 2023 - mdpi.com
Acquired Immunodeficiency Syndrome (AIDS) is a human viral infectious disease caused by
the positive-sense single-stranded (ss) RNA Human Immunodeficiency Virus …
the positive-sense single-stranded (ss) RNA Human Immunodeficiency Virus …
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1
H Azijn, I Tirry, J Vingerhoets… - Antimicrobial agents …, 2010 - Am Soc Microbiol
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) have proven efficacy against
human immunodeficiency virus type 1 (HIV-1). However, in the setting of incomplete viral …
human immunodeficiency virus type 1 (HIV-1). However, in the setting of incomplete viral …